Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas appoints VP, global medicine safety

This article was originally published in Scrip

Executive Summary

Astellas Pharma Global Development – a subsidiary of Astellas Pharma Inc, based in Tokyo, Japan – has appointed Robin J McGarry vice-president, global medicine safety head. For the past 13 years Ms McGarry worked as an independent consultant, providing pharmacovigilance, clinical, and regulatory strategic consulting services. And in the past she was vice-president of worldwide safety at Pfizer. Furthermore, Astellas Pharma Global Development has promoted Mark Weinberg to vice-president of Global Clinical Science at the company. Mr Weinberg joined Astellas in 2011 as global therapeutic area head in CNS and pain.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023246

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel